Senseonics Holdings, Inc. - Common Stock (SENS)

6.2600
+0.00 (0.00%)
NYSE · Last Trade: Feb 20th, 12:44 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close6.260
Open-
Bid6.170
Ask6.370
Day's RangeN/A - N/A
52 Week Range5.507 - 23.80
Volume0
Market Cap5.10B
PE Ratio (TTM)-12.78
EPS (TTM)-0.5
Dividend & YieldN/A (N/A)
1 Month Average Volume-

Chart

About Senseonics Holdings, Inc. - Common Stock (SENS)

Senseonics Holdings is a biomedical company specializing in the development and commercialization of innovative glucose monitoring systems for people living with diabetes. The company's flagship product is a long-term implantable continuous glucose monitoring (CGM) device that is designed to provide real-time glucose data to users, enhancing their ability to manage their condition effectively. By combining advanced sensor technology with a commitment to patient care, Senseonics aims to improve the quality of life for individuals with diabetes through more accurate and convenient monitoring options. Read More

News & Press Releases

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
By Sequel Med Tech · Via GlobeNewswire · February 19, 2026
Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system.
By Senseonics Holdings, Inc. · Via GlobeNewswire · January 29, 2026
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
By Senseonics Holdings, Inc. · Via GlobeNewswire · January 28, 2026
SENS Shares Surge After First Commercial Patients Use AID-Integrated Continuous Glucose Monitor Systemstocktwits.com
Via Stocktwits · January 8, 2026
Earnings Scheduled For November 5, 2025benzinga.com
Via Benzinga · November 5, 2025
Earnings Scheduled For August 6, 2025benzinga.com
Via Benzinga · August 6, 2025
Earnings Scheduled For May 8, 2025benzinga.com
Via Benzinga · May 8, 2025
Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update
Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year
By Senseonics Holdings, Inc. · Via GlobeNewswire · January 12, 2026
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System
twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM
By Senseonics Holdings, Inc. · Via GlobeNewswire · January 8, 2026
Benzinga Bulls And Bears: Applied Digital, NVIDIA, Senseonics — And Markets Fall On Fresh Tariff Fearsbenzinga.com
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · October 11, 2025
Senseonics Holdings's Earnings: A Previewbenzinga.com
Via Benzinga · May 7, 2025
Peering Into Senseonics Holdings's Recent Short Interestbenzinga.com
Via Benzinga · February 11, 2025
Senseonics Tumbles As Q3 Results And Split Hit Stockbenzinga.com
Senseonics stock drops on reverse split announcement despite record U.S. patient growth and 91% jump in Q3 revenue.
Via Benzinga · October 7, 2025
Aehr Test Systems Posts Q1 Earnings, Joins SANUWAVE Health And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 7, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · October 6, 2025
Wondering what's happening in today's after-hours session?chartmill.com
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · October 6, 2025
Forecasting The Future: 4 Analyst Projections For Senseonics Holdingsbenzinga.com
Via Benzinga · August 27, 2025
Curious about the stocks that are showing activity after the closing bell on Wednesday?chartmill.com
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · April 9, 2025
Earnings Scheduled For March 3, 2025benzinga.com
Via Benzinga · March 3, 2025
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 10, 2025
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · January 10, 2025
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 31, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 30, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 13, 2024
Eversense 365 Receives FDA Clearance: The World’s First One Year CGM
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the US Food and Drug Administration (FDA) has cleared the next-generation Eversense® 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. Eversense 365 is the world’s first One Year CGM system, representing a significant breakthrough in diabetes technology and management.
By Ascensia Diabetes Care · Via Business Wire · September 17, 2024